logo-loader
viewSilence Therapeutics PLC

Additional Listing

/**/ h1{margin-top:2.8pt;margin-right:0cm;margin-bottom:0cm;margin-left:24.85pt;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";}link{ color: blue }visited{ color: purple } .n{size:595.0pt 843.0pt;margin:99.0pt 61.0pt 14.0pt 63.0pt;}div.n{}p.d,li.d,div.d{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.ao{font-size:10.0pt;font-family:"Times New Roman","serif"}p.aq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:1.75pt;margin-right:2.5pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%}span.an{font-size:16.0pt;line-height:115%;font-family:"Calibri Light","sans-serif"; color:#234060}p.ar{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height:107%;text-autospace:ideograph-numeric ideograph-other}span.al{font-size:12.0pt;line-height:107%;font-family:"Calibri Light","sans-serif"; color:#234060}p.as{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:2.8pt;margin-right:14.95pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:115%}span.aj{color:black} p.at{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.05pt;margin-right:14.95pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:115%}p.au{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.av{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-left: 5.85pt; text-align: justify}p.aw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt;margin-right:0cm;margin-bottom:0cm; margin-left:5.85pt;margin-bottom:.0001pt}span.ae{font-size:10.0pt; color:black}table.ax{width:460.7pt;margin-left:3.4pt;border-collapse:collapse}tr.y{height:34.15pt}td.aa{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}p.ay{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 5.85pt; margin-right: 4.75pt; margin-top: 0cm; text-align: justify}p.az{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:4.75pt;margin-bottom: 0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify} td.z{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}tr.u{height:26.15pt}td.w{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}p.ba{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:5.85pt}td.v{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.t{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.s{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.bb{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt}span.q{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.bc{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify} p.bd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt} /**/
RNS Number : 7917I
Silence Therapeutics PLC
13 August 2019
 

 

Additional listing

August 13, 2019

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that yesterday it issued and allotted 200,000 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme.

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 16 August 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 77,911,652. The Company holds no shares in Treasury.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. 

 

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

 

Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSGGUAWRUPBGRP

Quick facts: Silence Therapeutics PLC

Price: 256

Market: AIM
Market Cap: £200.52 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

3 weeks ago